Profile data is unavailable for this security.
About the company
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
- Revenue in USD (TTM)7.88m
- Net income in USD-69.20m
- Incorporated2015
- Employees100.00
- LocationBolt Biotherapeutics Inc900 Chesapeake DriveREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 665-9295
- Fax+1 (302) 531-3150
- Websitehttps://boltbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ImmuCell Corp | 17.47m | -5.77m | 39.83m | 79.00 | -- | 1.58 | -- | 2.28 | -0.7454 | -0.7454 | 2.26 | 3.22 | 0.3941 | 1.96 | 8.86 | 221,160.40 | -13.03 | -5.16 | -14.19 | -5.53 | 22.15 | 40.04 | -33.05 | -12.64 | 0.8715 | -15.17 | 0.3238 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Unicycive Therapeutics Inc | 675.00k | -31.41m | 41.01m | 14.00 | -- | -- | -- | 60.76 | -1.62 | -1.62 | 0.0276 | -0.1096 | 0.0794 | -- | -- | 48,214.29 | -359.15 | -218.20 | -- | -609.54 | -- | -- | -4,525.04 | -3,877.49 | -- | -- | -- | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Aspira Women's Health Inc | 9.15m | -16.69m | 41.31m | 64.00 | -- | -- | -- | 4.51 | -1.73 | -1.73 | 0.9683 | -0.2222 | 0.7746 | 14.34 | 6.77 | 143,031.30 | -141.23 | -110.58 | -256.99 | -151.88 | 57.48 | 45.23 | -182.32 | -334.08 | 0.9871 | -- | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Quince Therapeutics Inc | 0.00 | -31.39m | 41.49m | 32.00 | -- | 0.4849 | -- | -- | -0.8424 | -0.8424 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | -23.09 | -42.72 | -24.22 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1363 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Carmell Corp | 0.00 | -16.88m | 41.88m | 9.00 | -- | 1.88 | -- | -- | -1.53 | -1.46 | 0.00 | 1.07 | -- | -- | -- | 0.00 | -- | -- | -- | -- | 58.60 | -- | -- | -- | -- | -194.46 | 0.0495 | -- | -- | -- | -75.70 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 7.88m | -69.20m | 41.94m | 100.00 | -- | 0.3719 | -- | 5.33 | -1.83 | -1.83 | 0.2083 | 2.96 | 0.0406 | -- | -- | 78,760.00 | -35.71 | -48.32 | -40.23 | -54.03 | -- | -- | -878.58 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Matinas BioPharma Holdings Inc | 1.10m | -22.94m | 42.14m | 32.00 | -- | 1.90 | -- | 38.45 | -0.1056 | -0.1056 | 0.005 | 0.0886 | 0.0314 | -- | -- | 34,250.00 | -65.62 | -44.62 | -72.81 | -48.25 | -- | -- | -2,093.25 | -2,344.60 | -- | -- | 0.0012 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| SensaSure Technologies Inc | 1.15k | -1.94m | 42.26m | 1.00 | -- | -- | -- | 36,749.47 | -0.0344 | -0.0344 | 0.00002 | -0.011 | 0.0336 | -- | -- | 1,150.00 | -5,689.09 | -- | -- | -- | -- | -- | -169,534.80 | -- | -- | -2.71 | -- | -- | -31.15 | -- | 17.62 | -- | -- | -- |
| Benson Hill Inc | 473.34m | -111.25m | 42.38m | 270.00 | -- | 0.4842 | -- | 0.0895 | -0.5914 | -0.6131 | 2.52 | 0.4129 | 1.22 | 10.27 | 14.81 | 1,753,096.00 | -28.68 | -- | -38.28 | -- | 4.99 | 3.18 | -23.50 | -40.73 | 0.9166 | -2.33 | 0.4509 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Dyadic International Inc | 2.90m | -6.80m | 42.69m | 7.00 | -- | 7.16 | -- | 14.73 | -0.2359 | -0.2359 | 0.1007 | 0.204 | 0.2643 | -- | 7.28 | 414,115.70 | -61.97 | -36.82 | -78.87 | -39.85 | 31.84 | 22.47 | -234.42 | -410.16 | -- | -- | 0.00 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Cara Therapeutics Inc | 20.97m | -118.51m | 43.19m | 55.00 | -- | 0.754 | -- | 2.06 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 43.94m | 8.00 | -- | 9.18 | -- | 40.82 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| IN8BIO, Inc. | 0.00 | -30.01m | 43.94m | 31.00 | -- | 1.73 | -- | -- | -1.02 | -1.02 | 0.00 | 0.5761 | 0.00 | -- | -- | 0.00 | -89.91 | -74.18 | -108.07 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Lexaria Bioscience Corp | 404.72k | -5.44m | 43.94m | 5.00 | -- | 6.48 | -- | 108.57 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Eyenovia Inc | 3.79k | -27.26m | 44.56m | 57.00 | -- | 4.43 | -- | 11,756.61 | -0.6639 | -0.6639 | 0.00009 | 0.1976 | 0.0001 | -- | 0.0031 | 66.49 | -91.15 | -80.31 | -119.11 | -117.70 | 0.00 | -- | -719,290.30 | -680.95 | 2.16 | -15.14 | 0.6135 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Movano Inc | 0.00 | -29.28m | 44.73m | 30.00 | -- | 7.37 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
Data as of May 07 2024. Currency figures normalised to Bolt Biotherapeutics Inc's reporting currency: US Dollar USD
29.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 31 Dec 2023 | 3.65m | 9.58% |
| Citadel Advisors LLCas of 31 Dec 2023 | 2.37m | 6.21% |
| Newtyn Management LLCas of 31 Dec 2023 | 1.55m | 4.08% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 931.13k | 2.44% |
| Stanford Management Co.as of 31 Dec 2023 | 719.55k | 1.89% |
| Adage Capital Management LPas of 31 Dec 2023 | 500.00k | 1.31% |
| Acuitas Investments LLCas of 31 Dec 2023 | 459.46k | 1.21% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 445.27k | 1.17% |
| Hawkeye Capital Management LLCas of 30 Sep 2023 | 415.04k | 1.09% |
| Geode Capital Management LLCas of 31 Dec 2023 | 350.16k | 0.92% |
More ▼
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
